All In Biotech

Drug Trial Radar · NCT06192264

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of ASC40 (Denifanstat) Tablets in Subjects With Moderate to Severe Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

480

Actual

Start

Jan 23, 2024

Primary completion

May 19, 2025

Study completion May 19, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of ASC40 (Denifanstat) tablets compared to placebo in the treatment of patients with moderate to severe acne vulgaris. The proposed plan for this trial is to enroll subjects who are 18-40 years of age (including borderline values), with a diagnosis of moderate to severe acne vulgaris, and an Investigator's Global Assessment (IGA) graded as moderate (grade 3) or severe (grade 4). 480 subjects were planned to be enrolled in the trial and placebo groups, with all subjects randomly assigned in a 1:1 ratio to receive either ASC40 (denifanstat) tablets dose 1 or placebo, administered orally once daily (taken after dinner) for 12 weeks. There will be a total of 6 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc..

Conditions

  • Acne

Interventions

  • ASC40Drug

    ASC 40 tablets orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of treatment success based on investigator's global assessment (IGA) in each group of subjectsTime frame: At Week 12 of treatment.
  2. Percentage change in total skin lesion counts compared to baseline ineach group of subjectsTime frame: At Week 12 of treatment.
  3. Percentage change in the count of inflammatory skin lesions compared to baseline in each group of subjectsTime frame: At Week 12 of treatment.

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Tsinghua Changgeng Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Shenzhen Hospital, The University of Hong Kong

    Shenzhen, Guangdong, China

  • The Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Guilin Medical College Affiliated Hospital

    Guilin, Guangxi, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangzhou, China

  • Shenzhen People's Hospital

    Shenzhen, Guangzhou, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Nanyang First People's Hospital

    Nanyang, Henan, China

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Changzhou First People's Hospital

    Changzhou, Jiangsu, China

  • Lianyungang First People's Hospital

    Lianyungang, Jiangsu, China

  • The First Affiliated Hospital of Gannan Medical College

    Ganzhou, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Xi'an Medical College

    Xi’an, Shanxi, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University School of Medicine

    Xi’an, Shanxi, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, China

  • Suining Central Hospital

    Suining, Sichuan, China

  • Tianjin Medical University General Hospital

    Tianjing, Tianjing, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Ningbo Second Hospital

    Ningbo, Zhejiang, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.